Medscape

First Omnipod 5 Algorithm Update Reflects User Requests

The US FDA has cleared the first updates to the algorithm of the Omnipod 5 automated insulin delivery (AID) system (Insulet ...
Healio

FDA clears updated algorithm with lower target glucose setting for Omnipod 5

The FDA cleared an updated algorithm for a hybrid closed-loop insulin delivery system that permits users to set a lower ...
FierceBiotech

Insulet widens launch of Omnipod 5 automated insulin pump

The dream of a completely closed-loop system for diabetes management is now closer than ever for many Type 1 diabetes patients, thanks to the widespread U.S. launch of a completely automated, ...
Seeking Alpha

Insulet Omnipod 5 insulin pump bests conventional delivery systems

Insulet (NASDAQ:PODD) announced Friday that its tubeless insulin delivery system, Omnipod 5, performed better than conventional insulin pumps in a clinical trial for patients with type 1 diabetes. Its ...
FierceBiotech

ADA: Insulet sets up wide-scale rollout of Omnipod 5 insulin pump

2022 is the year of the Omnipod 5 for Insulet. The year kicked off with FDA clearance for the latest generation of the insulin pump—which is tubeless, fully wearable and can be completely controlled ...
The Caledonian-Record

Insulet Announces FDA 510(k) Clearance of Omnipod® 5 Algorithm Enhancements that Redefine Insulin Delivery and Simplify the Pod Experience

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it has received FDA 510(k) ...
Nasdaq

Insulet Announces CE Mark Approval for Omnipod® 5 Automated Insulin Delivery System

ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced ...
Nasdaq

Insulet Announces Full Market Release of Omnipod® 5 Automated Insulin Delivery System

ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced ...
Benzinga.com

Omnipod Insulin Pump Working Well For Insulet, Lifts Annual Forecast

Insulet Corporation (NASDAQ:PODD) reported Q3 sales of $432.7 million, up 27.0%, or 25.1% in constant currency, beating the consensus of $414.383 million. Total Omnipod revenue of $422 million marked ...
ABC News

FDA approves 1st automated, tubeless insulin pump for people with Type 1 diabetes

The Omnipod 5 will be immediately available for people ages 6 to 70. A new technology for people with Type 1 diabetes, one that has been nearly a decade in the making, has been approved by the U.S.
Business Wire

Insulet Announces FDA Clearance of Omnipod GO™, a First-of-its-Kind Basal-Only Insulin Pod, Further Simplifying Life for People with Type 2 Diabetes

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced ...